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Abstract
Background: Clinical trial participants may be temporarily absent or withdraw from trials, leading to missing data.
In intention-to-treat (ITT) analyses, several approaches are used for handling the missing information - complete
case (CC) analysis, mixed-effects model (MM) analysis, last observation carried forward (LOCF) and multiple
imputation (MI). This report discusses the consequences of applying the CC, LOCF and MI for the ITT analysis of
published data (analysed using the MM method) from the Fracture Reduction Evaluation (FREE) trial.
Methods: The FREE trial was a randomised, non-blinded study comparing balloon kyphoplasty with non-surgical
care for the treatment of patients with acute painful vertebral fractures. Patients were randomised to treatment (1:1
ratio), and stratified for gender, fracture aetiology, use of bisphosphonates and use of systemic steroids at the time
of enrolment. Six outcome measures - Short-form 36 physical component summary (SF-36 PCS) scale, EuroQol 5-
Dimension Questionnaire (EQ-5D), Roland-Morris Disability (RMD) score, back pain, number of days with restricted
activity in last 2 weeks, and number of days in bed in last 2 weeks - were analysed using four methods for dealing
with missing data: CC, LOCF, MM and MI analyses.
Results: There were no missing data in baseline covariates values, and only a few missing baseline values in
outcome variables. The overall missing-response level increased during follow-up (1 month: 14.5%; 24 months:
28%), corresponding to a mean of 19% missing data during the entire period. Overall patterns of missing response
across time were similar for each treatment group. Almost half of all randomised patients were not available for a
CC analysis, a maximum of 4% were not included in the LOCF analysis, and all randomised patients were included
in the MM and MI analyses. Improved estimates of treatment effect were observed with LOCF, MM and MI
compared with CC; only MM provided improved estimates across all six outcomes considered.
Conclusions: The FREE trial results are robust as the alternative methods used for substituting missing data
produced similar results. The MM method showed the highest statistical precision suggesting it is the most
appropriate method to use for analysing the FREE trial data.
Trial Registration: This trial is registered with ClinicalTrials.gov (number NCT00211211).
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Background
The intention-to-treat (ITT) principle is one of the most
important approaches used in performing statistical ana-
lyses for randomised clinical trials [1]. It implies that for
all patients randomised to a treatment, data should be
analysed according to the treatment to which the patient
was allocated, irrespective of whether they received this
or some other treatment, or no treatment at all. Thus,
patients randomised to a control arm who actually
receive the treatment under investigation are regarded
as ‘controls’ rather than ‘treated cases’; in addition,
patients who fail to comply with their assigned treat-
ment are assessed as though the treatment was taken
correctly [2]. The purpose of the ITT principle is to pre-
serve the theoretical basis for the validity of the statisti-
cal results, specifically by eliminating the possibility that
patients with known or unknown prognostic factors are
systematically selected to a treatment [1].
Nonetheless, despite being reported as early as the
1960s [3], included in the International Conference on
Harmonisation (ICH) Good Clinical Practice (GCP)
guidelines [4], and being clearly described in methodolo-
gical papers specifically targeted at an orthopaedic audi-
ence [1], the ITT principle is not well known or
uniformly used by orthopaedic investigators. Indeed, a
recent systematic review (covering the years 2005-2008)
showed that the ITT principle was adhered to in only
96 out of 274 (35%) published orthopaedic randomised
trials [5].
It is not uncommon for patients participating in clini-
cal trials to be temporarily absent from follow-up visits
or terminate their involvement. When this happens,
some or all information on the treatment outcome for
these patients will not be available for the statistical ana-
lysis. Depending on the statistical method used, several
approaches are available for handling the missing infor-
mation in the ITT analysis. Either the available informa-
tion can be analysed in its current form, or the missing
data can be replaced with hypothetical observations
(imputed data) to allow patients for whom some data
are missing to be included in the analysis. The method
used to adjust for missing data should be chosen appro-
priately, depending on the reason for the missing data.
By imputing data (i.e. filling in missing values with
reasonable data), patients with some missing informa-
tion can be included in an analysis. In fact, inclusion of
patients with complete information only may not repre-
sent a randomly selected subset of the overall rando-
mized patient population. A complete-case (CC) analysis
includes only those patients with both baseline and cor-
responding follow-up outcome values and, as such, is at
variance with the ITT principle (which requires that all
cases, whether complete or incomplete, are included in
the analysis) [2]. An alternative for including all patients
is to perform a mixed-effects model (MM) analysis. By
modelling both random and fixed effects, this technique
can be used to analyse patients with incomplete follow-
up.
Missing data can be imputed via simple or multiple
imputation methodology. One of the most frequently
used simple imputation techniques is last observation
carried forward (LOCF). In this method, the last
observed values for a patient are used in place of the
missing values; this method assumes that the last known
state in the study represents the patient’s true outcome
[2]. This implicit assumption of representativity (which
is present in all simple imputation techniques) may be
considered a weakness, and should be questioned when
the treatment effect changes during follow-up. Further-
more, simple imputation techniques are deterministic
and lead to an underestimation of the variability in the
outcome.
In contrast, multiple imputation (MI) is a stochastic
technique which depends on model-based imputation of
multiple values for each missing observation. The values
are combined using the technique described by Rubin in
1987 [6]. Thus, MI provides a superior alternative to
simple imputation. It does not underestimate variability,
and the models for imputation and efficacy analysis can
be developed independently, thereby increasing the rea-
lism of the assumptions underlying the imputation [2].
The advantages provided by the most recently devel-
oped techniques, such as MM and MI (compared with
CC and LOCF), are also associated with much greater
complexity. As a consequence, widespread application of
these techniques may be delayed because those unfami-
liar with the methodology could have concerns about
the validity of the results generated. Thus, further dis-
cussion about the importance of the ITT principle,
along with greater understanding of the problems asso-
ciated with missing values in orthopaedic randomised
trials, is required.
The aim of this report is to describe and discuss the
consequences of applying the three alternative methods
(CC, LOCF and MI) for the ITT analysis of the Fracture
Reduction Evaluation (FREE) trial - a randomized con-
trolled trial of balloon kyphoplasty (BKP) versus non-
surgical care for vertebral compression fracture, analysed
using the MM method and recently published in The
Lancet [7].
Materials and methods
The Fracture Reduction Evaluation (FREE) trial
Detailed methodology for the FREE trial has been pre-
sented previously [7]. In brief, the FREE trial was a ran-
domised, non-blinded trial comparing non-surgical care
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alone with BKP for the treatment of patients with acute
painful vertebral fractures. The study included patients
from 21 sites in eight countries (Austria, Belgium,
France, Germany, Italy, Sweden, the Netherlands and
the United Kingdom) and was conducted from February
2003 through December 2005.
All participants had at least one acute thoracic or
lumbar (T5-L5) vertebral fracture with bone marrow
signal changes on magnetic resonance imaging (MRI),
and vertebral height reduction (> 15% of predicted ver-
tebral height) compared with the adjacent vertebrae.
Painful vertebral fractures were diagnosed by the local
investigator; up to three fractures could be treated if
they also had signal changes, rapidly progressive height
loss or pseudoarthrosis.
Participants had self-assessed back pain of at least 4
on a scale from 0 (no pain) to 10 (worst pain imagin-
able) that started within the past 3 months and was not
attributable to other causes. Vertebral fractures were
included irrespective of aetiology; however, fractures due
to primary bone tumours, osteoblastic metastases or
high-energy trauma were excluded. Participants gave
written informed consent before enrolment, and the
protocol and consent forms were approved by local
ethics committees. The trial was conducted in accor-
dance with the Declaration of Helsinki, and is registered
with ClinicalTrials.gov (number NCT00211211).
Patients were randomly assigned in a 1:1 ratio to
receive BKP or non-surgical care using a computer-gen-
erated schedule. Study randomisation was stratified for
gender, fracture aetiology, use of bisphosphonates at the
time of enrolment and use of systemic steroids during
the last 12 months before enrolment, but not for num-
ber of prevalent fractures per participant. A permuted
block randomisation (stratified as indicated) was gener-
ated using PROC PLAN prior to the start of the study.
Percutaneous BKP was performed with introducer
tools, inflatable bone tamps, and polymethylmethacrylate
bone cement and delivery devices (Medtronic Spine
LLC, Sunnyvale, CA, USA) using a bilateral, transpedi-
cular or extrapedicular approach. Patients received
analgesics, bed rest, bracing, physiotherapy, rehabilita-
tion programmes and walking aids according to the
standard practices of participating physicians and hospi-
tals. All patients were referred for treatment with cal-
cium and vitamin D supplements, and antiresorptive or
anabolic agents.
The primary endpoint was the change from baseline
to 1 month in quality of life (QoL) assessed using the
Short-form 36 (SF-36) physical component summary
(PCS) scale. Secondary endpoints included: EuroQol 5-
Dimension Questionnaire (EQ-5D); SF-36 subscale
scores; function measured using the Roland-Morris Dis-
ability (RMD) score; back pain assessed with a visual-
analogue scale (VAS; scale 0-10); limited days of activity
and bed rest because of back pain during the previous 2
weeks; and patient satisfaction assessed on a 20-point
Likert scale (extremely dissatisfied to extremely satis-
fied). Outcomes were assessed at baseline/screening and
at 1, 3, 6, 12 and 24 months; back pain was also
assessed at 7 days.
Statistical methods
Six outcome measures - SF-36 PCS scale, EQ-5D, RMD
score, back pain, number of days with restricted activity
in last 2 weeks and number of days in bed in last 2
weeks - were analysed using four methods for dealing
with missing data: CC analysis, simple imputation with
LOCF analysis, MM analysis on all available data and
MI analysis.
The CC analysis included only patients with both
baseline and all follow-up values for respective out-
comes. For the LOCF analysis, only patients with avail-
able baseline values were included; missing follow-up
values were replaced by the patient’s last observed value,
based on the assumption that this represented the treat-
ment effect. In contrast with the LOCF method, MI is a
stochastic imputation method based on the assumption
that missing values can be replaced with values gener-
ated by a model incorporating random variation. The
generation of such values is performed repeatedly pro-
viding a series of complete datasets. These datasets are
then analysed using standard methods for complete
data, and the results are combined to provide a set of
parameter estimates and their standard errors, from
which confidence intervals and p-values can be derived.
The MI model can be different from the model used for
the final data analysis. In this study we imputed data
using as-treated models, and analysed them according to
ITT [2].
For the CC, LOCF and MI methods, the analysis was
performed using a conventional repeated-measures
ANOVA design. The model included treatment group
and visit as fixed factors, as well as their interaction,
together with covariates representing the randomisation
stratification factors (gender, fracture aetiology, use of
bisphosphonates at the time of enrolment and use of
systemic steroids during the last 12 months before
enrolment) and baseline values.
In the MM analysis, all patients with at least one base-
line or follow-up value were included. An MM analysis
includes both fixed and random factors: in the current
analysis, treatment group and visit were included as
fixed factors, and patient was included as a random fac-
tor. The model included interactions between treatment
and visit. Randomisation stratification factors (gender,
fracture aetiology, use of bisphosphonates at the time of
enrolment and use of systemic steroids during the last
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12 months before the time of enrolment) and baseline
value were included as covariates. Compound symmetry
structure for covariance between measurements was
assumed. Maximum restricted likelihood procedure was
used to fit the model and denominator degrees of free-
dom were estimated using Satterthwaite’s approxima-
tion. This mixed model analysis is, with balanced data,
equivalent to the conventional repeated measures
ANOVA with sphericity assumption [8].
Assumptions
The CC approach assumes that data are missing com-
pletely at random (MCAR) - i.e. that missing data are a
random subsample of all data. The LOCF approach
assumes that baseline values are MCAR, and that there
is no change in treatment effect during follow-up. It is
also assumed that there is no variation in the measure-
ment of treatment effect itself. In both the MM analysis
and the MI technique, it is assumed that data are miss-
ing at random (MAR), meaning that the probability that
an observation is missing may depend on observed data
but not on missing data. Thus, the likelihood function
for the complete dataset, with respect to inference on
the unknown parameters that characterise the complete
data distribution, is the same as the likelihood function
for the observed data. In the MM approach, the MAR
assumption needs to be fulfilled in the analysis model,
whereas in the MI approach only the imputation model
needs to satisfy the MAR assumption.
Imputation model
In this study, the imputation model included all six out-
comes at baseline and follow-up visits, all randomisation
stratification factors, age, treatment centre and number
of fractures at baseline (≥ 1), in addition to treatment
‘as received’. Treatment centres with less than 7% of
patients overall were combined. Treatment ‘as received’,
rather than treatment ‘as randomised’, was used in the
imputation model to recover the ‘true’ outcome values
for patients. This was done because the observed out-
come values for the patient are influenced by the treat-
ment received not the treatment assigned.
Multiple imputation using fully conditional specifica-
tion (or ‘chained equations’) [9] was used to create 30
imputed datasets, primarily because the distribution of
number of days with reduced activity and number of
days in bed were substantially non-normal. Therefore,
the variables were treated as ordinal in the imputation
model. Other outcome variables were treated as contin-
uous. PCS followed a normal distribution and was not
transformed. Roland-Morris disability score, VAS and
EQ-5D were transformed to normality using Box-Cox
transformation and imputed with predictive mean
matching method [10] to ensure that the imputed values
did not exceed the natural range of values for those
variables. After imputation the values were transformed
back to the original scale. Other covariates were
included as dummy (0-1) variables. To create the impu-
tation in STATA the imputation by chained equations
(ICE) implementation was used [11].
The MI approach provides the means to estimate the
fraction of missing information relative to the complete
information for each parameter of interest.([6], section
3.3) If the missing data do not provide any additional
information about the parameter of interest to that
which can be observed from the available data then the
fraction will be equal to zero. If the missing data contain
a high proportion of information, and this is not also
contained within the observed data, then the fraction of
missing information will be high.
Results
Missing response
There were no missing data in baseline covariates
values, and only a few missing baseline values in out-
come variables. The missing-response level increased
during follow-up from an average of 14.5% at 1 month
to 28% at 24 months; corresponding to a mean of 19%
missing data during the entire follow-up period. Of the
six outcome variables, back pain had the highest avail-
able response level (83.4%) and RMD score had the low-
est (77.2%; Table 1). Overall patterns of missing
response across time were similar in both treatment
groups, with consistently higher available response in
the BKP group than in the control group (mean 9%
higher for all outcome variables, with the exception of
the RMD score where the difference between treatments
was approximately 3%; Figure 1).
Estimated fraction of missing information
The fraction of missing information can be used instead
of the traditional percentage of missing values to assess
the level of missing response in surveys [12]. It does not
need to be equal to the nominal amount of missing
values, but can be smaller if there is information about
missing data in other correlated and observed variables,
or larger if patients with missing values have more influ-
ence on regression coefficients than patients with
observed values. The fraction of missing information
and nominal percentage of missing values for each of
the six outcomes are presented in Table 2. With the
exception of ‘days in bed’, the fraction of missing infor-
mation estimated using the MI method was lower than
the nominal percentage of missing data per visit.
Comparison of analysis methods
Results for the analysis of variance with repeated mea-
sures on the CC dataset, the dataset imputed with
LOCF method, and datasets resulting from the MI pro-
cedure and MM analysis on all available data are shown
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in Table 3. Complete-case analyses were performed on
62%, 64%, 49%, 62%, 54% and 66% of patients for SF-36
PCS, EQ-5D, RMD score, number of days in bed, num-
ber of days with restricted activity, and back pain,
respectively. Almost half of all randomised patients were
not available for a CC analysis. A maximum of 4% of
patients were not included in the LOCF analysis because
of missing baseline values. All randomised patients were
included in the MM and MI analyses.
The consequences for these approaches are, inter alia,
differences in size of standard errors of the estimates.
The standard errors (SE) were compared with those
from CC, which was used as the reference method. The
mean squared errors (MSE) from CC, LOCF, MM and
MI were calculated with means of the estimates from all
four methods as reference values. The percentage reduc-
tions in size of SE and MSE in estimates of treatment
effect at five follow-up periods are presented in Figure 2
and 3.
The highest percentage reductions in standard errors
at all follow-up months were observed with the LOCF
analysis, about 20% for all outcomes apart from days in
bed; MM showed higher (3% on average) percentage
reductions in standard errors than MI at each follow-up
month. However, it should be noted that LOCF has the
potential of underestimating the true standard error, as
it assumes no variation in the observations carried for-
ward, so it may not be as reliable as the other two
imputation methods.
Percentage reductions in size of standard errors
compared with CC for overall treatment effect are pre-
sented in Figure 4. The reductions achieved when
using the imputation methods (LOCF, MM, and MI)
allow more precise estimates of the treatment effect to
be generated for each outcome. For five of the out-
comes, all three methods provided percentage reduc-
tions in standard error compared with CC for overall
treatment effect (Figure 4). However, for the outcome
‘days in bed’ only the MM method provided a reduc-
tion in size of standard errors, between 1% and 6%
(Figures 2 and 4). A reduction was observed at most
timepoints (months 1-12) with the MM method,
whereas increases in standard error were observed
across all follow-up timepoints (months 1-24) for
LOCF and MI methods (Figure 2).
These findings are supported by the comparisons of
MSEs (Figure 3), which also show that the MM and MI
approaches tend to yield more precise estimates,
whereas the CC analysis tend to result in lower preci-
sion, at least for other outcomes than “days in bed”.
Discussion
The different analysis methods (CC, LOCF, MM and
MI) applied to the FREE trial data produced similar
results, with only minor differences in standard error
sizes observed between the groups. This suggests that
the FREE trial data are not dependent on the ITT analy-
sis method used. Indeed, the information contained
within the missing data would seem to be of a similar
nature to the actual documented information. This
implies that the conclusions made about the efficacy of
BKP treatment in the FREE trial are robust.
The literature shows that use of the ITT principle in
orthopaedic randomized clinical trials (RCT) is limited;
in a survey of eight leading orthopaedic journals only
35% of RCT used the ITT method [5]. Thus, lack of
ITT use could be a potential source of bias for a com-
paratively large proportion of orthopaedic RCT. Similar
investigations have previously been performed for the
general medical literature: an analysis of four leading
medical journals demonstrated that 119 out of 249
(48%) RCT published in 1997 used the ITT principle
[13], while a later analysis of ten medical journals
showed that 249 out of 403 (62%) RCT published in
2002 used the ITT method [14]. Therefore, while the
ITT principle appears to be more commonly used in
general medical RCT compared with orthopaedic RCT,
there is still scope for improvement.
In the FREE study, the missing response level was
19% for the entire 24-month follow-up period. This
proportion was similar to that observed for other long-
term studies; in a survey of RCT published in eight
Table 1 Percentage missing data in the FREE trial overall
Follow-up (time after randomisation)
Measure Baseline 1 month 3 months 6 months 12 months 24 months Mean
SF-36 PCS 2.7 13.0 19.7 21.0 25.0 27.3 18.1
EQ-5D 2.3 13.0 19.3 20.7 24.7 25.3 17.6
RMD score 1.7 15.7 25.0 26.7 32.0 36.0 22.8
Back pain 0.7 12.0 18.0 19.7 24.7 24.3 16.6
Restricted activity 4.0 18.0 22.3 22.0 26.0 28.3 20.1
Days in bed 3.3 15.3 20.7 20.7 24.7 27.0 18.6
Values shown are percentages
EQ-5D, EuroQol 5-dimension; RMD, Roland-Morris Disability; SF-36 PCS, short form-36 physical component summary
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orthopaedic journals the mean rate of patients lost to
follow up was 17% for thirty studies with a follow-up
period longer than 1 year [5]. Indeed, increased missing
response levels in RCT may be expected over longer
time periods; in the same survey of orthopaedic RCT a
significant increase in the proportion of patients with
missing data was observed over longer follow-up peri-
ods [5].
Figure 1 Missing data by treatment group in the Fracture Reduction Evaluation (FREE) trial. EQ-5D, EuroQol 5-dimension; RMD, Roland-
Morris Disability; SF-36 PCS, short form-36 physical component summary.
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While each imputation method provided similar
results, there are certain characteristics related to each
analysis method that need to be acknowledged. For
example, the CC analysis (which is at variance with the
ITT principle) is generally considered insufficient for
evaluating data from clinical trials. Data can be missing
in a sporadic manner across several different covariates
and this can lead to the omission of a high proportion
of patients for a CC analysis. Indeed, in the FREE trial
almost half of all randomised patients were not available
for the CC analysis. It is possible that only including
patients with complete information may not provide a
representative randomly selected subset of the total ran-
domised population. The higher MSE for the CC analy-
sis can also be interpreted as a sign of bias in the
treatment effect estimate. However, in the FREE study
the results obtained for the CC analysis were reasonably
consistent with the MM, not being an imputation
method, and MI suggesting those patients with complete
information were representative of the randomised
population.
The Cochrane Musculoskeletal Group recommends
that imputations based on methods such as LOCF are
acceptable in both ‘platinum’ and ‘gold’ level publica-
tions included in Cochrane systematic reviews [15].
Implicit in the LOCF method is the assumption that the
outcome remains constant from the last observed value
after drop out and that no measurement errors exist,
otherwise there is a risk for bias particularly over longer
follow-up periods. In the FREE trial treatment effects
were actually observed to change during the follow-up
period [7]. At 1 month follow-up, patients treated with
BKP showed significantly (p < 0.0001) greater improve-
ments in SF-36 PCS score compared with those who
received non-surgical treatment. However, at 12-months
follow-up the difference between the two groups had
diminished likely due to fracture healing in patients who
had received non-surgical treatment. Therefore, use of
LOCF to analyze the FREE trial data could be a poten-
tial source of bias. However, the present analysis showed
that the LOCF method produced similar results to the
MM and MI methods suggesting that any potential
effects on bias would likely be minimal.
The MI method does not have the disadvantages asso-
ciated with single imputation methods: variance is not
underestimated and treatment effect changes are pre-
served over time. The MI method does rely to a great
extent on the imputation model being correct, but pro-
viding the data are normally distributed or can be trans-
formed to normality there is a sound theoretical
background to how the imputations are generated [16].
However, if some of the imputed variables cannot be
treated as normally distributed then other MI methods,
such as chained equations, need to be used. The chained
equations method has produced accurate imputations in
various settings [9], but the overall theory that proves
its correctness is currently being developed. The inclu-
sion of more variables in the imputation model than in
the analysis model increases the probability that MAR
assumptions hold, although this may lead to an increase
in the standard errors of the final estimates [16]. In case
the imputation model and the analysis models differ it is
crucial to ensure that the models are congenial, i.e. that
all variables used in the analysis model are included in
the imputation model [17].
When surgical intervention in one group is compared
with a non-surgical treatment in another, the propor-
tions of patients lost to follow up could be expected to
differ between the groups. The phenomenon has been
described earlier [5], and it occurs also in this trial. The
higher rate of missing data in the control group may
undermine a MAR assumption, which would affect both
the MM and CC analysis. However, if the MAR assump-
tion holds for the analysis model used then MI should
converge to MM as the number of imputations goes to
infinity [18]. For the FREE data there were no substan-
tial differences observed between the MM and MI ana-
lyses despite the fact that the imputation model
included more variables than the analysis model. This
indicates that the MAR assumption holds for the analy-
sis model and that the MM analysis method appears to
be optimal.
In the present analysis of the FREE data, the MM
method showed the highest statistical precision without
the unsubstantiated assumptions required for LOCF.
This was particularly evident when the three methods
(LOCF, MM and MI) were used to examine the percen-
tage reduction in standard error compared with CC for
overall treatment effect. Only MM provided a reduction
Table 2 Fraction of missing information compared with
the nominal amount of missing information
Follow-up period
1 month 3
months
6
months
12
months
24
months
Outcome FMI MD FMI MD FMI MD FMI MD FMI MD
SF-36 PCS 11.9 15.7 15.8 22.3 17.2 23.7 23.9 27.7 30.1 30.0
EQ-5D 14.5 15.3 13.1 21.7 18.0 23.0 18.4 27.0 20.9 27.7
RMD 9.9 17.3 19.8 26.7 18.2 28.3 21.0 33.7 19.9 37.7
Back pain 12.3 12.7 15.7 18.7 19.0 20.3 17.3 25.3 29.6 25.0
Restricted
activity
9.6 22.0 14.0 26.3 19.6 26.0 19.3 30.0 20.0 32.3
Days in bed 21.2 18.7 24.6 24.0 27.5 24.0 35.4 28.0 34.3 30.3
Values shown are percentages
EQ-5D, EuroQol 5-dimension; FMI, fraction of missing information; RMD,
Roland-Morris Disability; SF-36 PCS, short form-36 physical component
summary; MD, nominal amount of missing data in baseline and follow-up
data
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Figure 2 Percentage reduction in standard error for all follow-up visits for six outcomes. Five outcomes assessed were: short form-36
physical component summary, EuroQol 5-dimension, Roland-Morris Disability, visual analogue scale and restricted activity. CC, complete case;
LOCF, last observation carried forward; MI, multiple imputation; MM, mixed-effects model; SE, standard error.
Figure 3 Mean squared error for all follow-up visits for six outcomes, mean of the estimates from all 4 methods used as reference
value. Five outcomes assessed were: short form-36 physical component summary, EuroQol 5-dimension, Roland-Morris Disability, visual analogue
scale and restricted activity. CC, complete case; LOCF, last observation carried forward; MI, multiple imputation; MM, mixed-effects model; SE,
standard error.
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in variance across all six outcomes measured (including
‘days in bed’). The MI method also provided low var-
iance but was not as precise as the MM method across
all outcomes considered. This suggests that application
of the MM method is probably the most accurate
approach for analysing these data. This suggestion is
also supported by a simulation study [18].
Conclusions
The FREE trial results are robust as the four alternative
methods used for substituting missing data produced
similar results. The small differences observed for the
MM and MI models provide strong support for their
use. By comparison the CC model included only
approximately half of the ITT population and LOCF
appeared to overestimate precision, which could poten-
tially produce biased results.
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